Need treatment? Find help or get online counseling right now!

Archives for Atypical Antipsychotic

Evidence for Abilify (Aripiprazole) in Maintenance of Bipolar Disorder Questioned

Abilify (aripiprazole) is an atypical antipsychotic medication commonly used to treat schizophrenia and acute mania. In 2005, the Food and Drug Administration (FDA) approved its use in the maintenance treatment of bipolar disorder – to prevent the recurrence of mood episodes. Unfortunately, evidence proving the effectiveness of Abilify as a maintenance medication for bipolar disorder is scarce and questionable.

Exposing the Truth


An article published this week in the open access journal PLoS Medicine (Tsai et al) looks critically at the scientific evidence that...
Continue Reading

Antipsychotic

Long-Term Antipsychotic Use May Reduce Brain Volume

Until recently, doctors and researchers had believed that brain volume loss in schizophrenia was caused primarily by the disease itself. One recent study, however, questions this long-held belief and identifies antipsychotics, the medications most commonly used to treat schizophrenia, as the more likely culprits.

With the increased long-term use of antipsychotics to treat schizophrenia and other forms of mental illness, especially bipolar mania, it's important to determine whether...
Continue Reading

Antipsychotic

FDA Update on the Use of Antipsychotics During Pregnancy

The Food and Drug Administration (FDA) is informing healthcare professionals that it has updated the Pregnancy section of drug labels for the entire class of antipsychotic drugs. The new drug labels now contain more and consistent information about the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy.
For details,...
Continue Reading

Bipolar Disorder Medication Spotlight: Saphris

Genetic Engineering & Biotechnology News recently ran a brief article entitled "EU Sanctions Merck & Co.'s Sublingual Bipolar Disorder Drug Sycrest." Sycrest was first approved in the in 2009 where Merck markets it as Saphris. Sycrest/Saphris is a "sublingual asenapine drug for treating moderate to severe manic episodes in adult patients with bipolar I disorder" and for treating schizophrenia. When used in treating bipolar disorder mania, it is most effective when used with other anti-manic medications, including lithium and Depakote.

Saphris/asenapine is the...
Continue Reading

12